Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3368111 | 0.95 | CYP11B1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL3368899 | 0.93 | CYP11B1 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL3369877 | 0.91 | KDM4E (0.33) | — | |
| SCHEMBL3368835 | 0.89 | KDM4E (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL3368990 | 0.89 | CYP11B1 (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL3401093 | 0.84 | CYP11B1 (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL3368891 | 0.83 | CYP11B2 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL3366305 | 0.80 | CYP17A1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL3366407 | 0.79 | FASN (0.37) | — | |
| SCHEMBL3365832 | 0.79 | FASN (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324235-B2 | Heterocyclic spiro-compounds | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| EP-2134720-B1 | HETEROCYCLIC SPIRO-COMPOUNDS | NOVARTIS AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-20100144774-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144774-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | REN, NR3C2, CYP21A2 | CYP11B1 4/4885CYP11B2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.